Evidence map›Paper›PMID 40778224›Full record

ArticleFrontiers in genetics2025

Integrated cytomembrane proteomics identifies EpCAM/MGST1 as therapeutic targets in metastatic laryngeal carcinoma.

Suling Zhuang, Xiaobo Wu, Xiaohuang Lin, Zhihan Li, Di Gan, Shixin Wang, Xue Lin, Gongbiao Lin, Miao Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suling Zhuang *Department of Otorhinolaryngology Head and Neck Surgery, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xiaobo Wu *Department of Otorhinolaryngology Head and Neck Surgery, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xiaohuang LinKey Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Zhihan LiKey Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Di GanKey Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Shixin WangKey Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Xue LinDepartment of Gastrointestinal Surgery, Gutian County Hospital of Fujian Province, Ningde, Fujian, China.
Gongbiao LinDepartment of Otorhinolaryngology Head and Neck Surgery, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Miao GaoDepartment of Otorhinolaryngology Head and Neck Surgery, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lymph node metastasis plays a crucial role in cancer recurrence and survival, however, the underlying molecular mechanism and biomarkers in laryngeal carcinoma remain poorly characterized. While cytomembrane proteins represent attractive therapeutic targets due to their accessibility, the identification of tractable candidates for precision therapy remains challenging. Methods: This study aimed to identify potential therapeutic targets for laryngeal squamous cell carcinoma (LSCC) with lymph node metastasis through cytomembrane proteome profiling. We conducted a comprehensive multi-omics analysis in 158 LSCC cases from TCGA (111 patients) and CPTAC (47 patients) database. The correlations between lymph node metastasis and molecular features at proteome levels were investigated. Potential immunotherapy targets were identified and prioritized using an Results: The Conclusion: Integrated cytomembrane proteomics in metastatic LSCC unveils EpCAM/MGST1 as actionable immunotherapeutic targets, with silencing attenuating oncogenic proliferation, invasion, and Wnt/β-catenin-PI3K crosstalk, offering novel therapeutic avenues.

Indexed as

cytomembrane proteinEpCAMLSCClymph node metastasisMGST1MGST1 lymph node metastasis

Identifiers

PMID40778224
PMCPMC12328148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.